flagellin + toll-like receptor 5 antibody

The combination of **flagellin** and a **toll-like receptor 5 (TLR5) antibody** refers to a therapeutic strategy or experimental regimen involving the activation or modulation of the TLR5 signaling pathway. Flagellin is a bacterial structural protein that serves as the natural ligand and potent agonist for TLR5, a pattern recognition receptor that triggers the NF-κB signaling cascade to initiate innate and adaptive immune responses. Pharmaceutical derivatives of flagellin, such as **entolimod** (CBLB502), have been developed for radiation protection (by preventing apoptosis in hematopoietic and gastrointestinal cells) and as cancer immunotherapies. The antibody component typically refers to monoclonal antibodies that target TLR5, which can be categorized as either **agonists** (e.g., **KVA12123**), designed to mimic flagellin's activity for oncology indications, or **antagonists** (e.g., **PF-06743649**), intended to suppress TLR5-mediated inflammation in conditions like inflammatory bowel disease (IBD). Preclinical research has demonstrated that certain anti-TLR5 antibodies (such as the 10E7 clone) can synergistically enhance flagellin-induced TLR5 activation, potentially creating a "super-agonist" effect for treating advanced solid tumors.

Other names

Flagellin-TLR5 combinationFlagellin-TLR-5 combinationFlagellin-TLR 5 combinationTLR5 agonist combinationTLR-5 agonist combinationTLR 5 agonist combinationFlagellin-mimetic antibody combination